SCHEMBL1307192

SCHEMBL1307192

O=C(Cc1ccc(Cl)cc1)Nc1c(Br)cc(Br)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
LMNA P02545 2/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KDM5A P29375 1/20 0.50
KDM4C Q9H3R0 1/20 0.50
KDM5B Q9UGL1 1/20 0.50
CA12 O43570 3/20 0.48
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA9 Q16790 3/20 0.48
NLRP3 Q96P20 1/20 0.48
MAPT P10636 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
EGFR P00533 2/20 0.44
ERBB2 P04626 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1308232 0.86 MEN1 (0.60) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL1308047 0.84 GALR3 (0.47) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL1307619 0.80 KMT2A (0.72) MEN1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL1307683 0.80 PRSS12 (0.56) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL1308435 0.80 KCNJ5 (0.49) MEN1KMT2ALMNACA12CA1
SCHEMBL3089726 0.78 MEN1 (0.60) MEN1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL1309256 0.73 MEN1 (0.78) MEN1KMT2ALMNASMN1; SMN2KDM5A
SCHEMBL4736482 0.72 SMN1; SMN2 (0.52) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL6714065 0.72 METAP2 (0.66) ALDH1A1
SCHEMBL16496229 0.71 KDM5A (0.60) MEN1KMT2ALMNAKDM5AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US claimed
WO-2004022525-A1 AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO claimed
US-8053454-B2 Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2011-11-08 US disclosed
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US disclosed
WO-2004022525-A1 AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 PIM1, PIM3, PIM2 MEN1 2312/4885KMT2A 1570/4885LMNA 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.